Nucleic acid therapies: Towards cardiac-specific recombinant adeno-associated viruses (rAAVs) of human origin: Directed evolution and characterization of novel AAV variants isolated from human failing hearts in models with human relevance and relevance fo
- Förderkennzeichen
81X2500195
- Projektnummer
1326
- Institution
- Universität Heidelberg
- Projektleiter
- Patrick Most
- Standort
- Heidelberg/Mannheim
- Projektart
- Innovation Cluster
- Fördersumme
- € 607.835,00
- Beginn
- 01.01.2021
- Ende
- 31.12.2024
- Partnerprojekte